HIGHLIGHTS
- who: Rita Terenziani et al. from the Department of Medicine and Surgery, University of Parma, Parma, Italy have published the article: CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells, in the Journal: Cancers 2022, x of /2022/
- what: The authors evaluated the antitumor potential of combining the standard chemotherapy regimen used for unresectable MPM with the CDK4/6 (cyclin-dependent kinase or inhibitor abemaciclib. Since the simultaneous combination produced the strongest inhibition of cell proliferation, the authors focused on this schedule.
- how: The authors evaluated the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.